Publication:
Serum malondialdehyde levels, myeloperoxidase and catalase activities in patients with nephrotic syndrome

dc.contributor.authorBeğenik, Hüseyin
dc.contributor.authorSoyoral, Yasemin
dc.contributor.authorErkoc, Reha
dc.contributor.authorEmre, Habib
dc.contributor.authorTAŞKIN, ABDULLAH
dc.contributor.authorTasdemir, Mehmet
dc.contributor.authorAslan, Mehmet
dc.date.accessioned2020-10-22T18:04:17Z
dc.date.available2020-10-22T18:04:17Z
dc.date.issued2013-05-01T00:00:00Z
dc.description.abstractObjectives: Some studies have indicated the pathophysiological importance of reactive oxygen species (ROS) in patients with nephrotic syndrome. Myeloperoxidase (MPO) is a leukocyte-derived enzyme-generating ROS that has been proposed to exert a wide array of pro-atherogenic effects throughout all stages of the atherosclerotic process. The aim of this study was to investigate the serum malondialdehyde (MDA) levels, MPO and catalase activities in patients with adult nephrotic syndrome.
dc.identifier.citationBeğenik H., Soyoral Y., Erkoc R., Emre H., TAŞKIN A., Tasdemir M., Aslan M., -Serum malondialdehyde levels, myeloperoxidase and catalase activities in patients with nephrotic syndrome-, REDOX REPORT, cilt.18, ss.107-112, 2013
dc.identifier.doi10.1179/1351000213y.0000000048
dc.identifier.pubmed
dc.identifier.scopus84878994260
dc.identifier.trdizintrdizin
dc.identifier.urihttp://hdl.handle.net/20.500.12645/23940
dc.identifier.wosWOS:000320451000004
dc.subjectnephrotic syndrome
dc.titleSerum malondialdehyde levels, myeloperoxidase and catalase activities in patients with nephrotic syndrome
dc.typeArticle
dspace.entity.typePublication
local.avesis.id705e3bb6-249c-451f-8899-c3fe303f15d8
local.indexed.atPubMed
local.indexed.atWOS
local.indexed.atScopus
local.indexed.atTrDizin
local.publication.isinternational1

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
YRER_18_11756946.pdf
Size:
184.59 KB
Format:
Adobe Portable Document Format
Description: